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Abstract
Many inflammatory diseases may be linked to pathologically elevated signaling via the receptor for lipopolysaccharide (LPS),
toll-like receptor 4 (TLR4). There has thus been great interest in the discovery of TLR4 inhibitors as potential anti-
inflammatory agents. Recently, the structure of TLR4 bound to the inhibitor E5564 was solved, raising the possibility that
novel TLR4 inhibitors that target the E5564-binding domain could be designed. We utilized a similarity search algorithm in
conjunction with a limited screening approach of small molecule libraries to identify compounds that bind to the E5564 site
and inhibit TLR4. Our lead compound, C34, is a 2-acetamidopyranoside (MW 389) with the formula C17H27NO9, which
inhibited TLR4 in enterocytes and macrophages in vitro, and reduced systemic inflammation in mouse models of
endotoxemia and necrotizing enterocolitis. Molecular docking of C34 to the hydrophobic internal pocket of the TLR4 co-
receptor MD-2 demonstrated a tight fit, embedding the pyran ring deep inside the pocket. Strikingly, C34 inhibited LPS
signaling ex-vivo in human ileum that was resected from infants with necrotizing enterocolitis. These findings identify C34
and the b-anomeric cyclohexyl analog C35 as novel leads for small molecule TLR4 inhibitors that have potential therapeutic
benefit for TLR4-mediated inflammatory diseases.
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Introduction
The innate immune receptor toll-like receptor 4 (TLR4) has
been recognized as the receptor on hematopoietic and non-
hematopoietic cells for bacterial endotoxin (lipopolysaccharide,
‘‘LPS’’) [1], as well as for a variety of endogenous molecules that
are released during inflammatory or infectious disorders [2]. A
number of diseases have been attributed to exaggerated TLR4
signaling, including both infectious and non-infectious processes.
These include necrotizing enterocolitis (NEC) [3], abdominal
sepsis [4], pneumonia [5], arthritis [6], pancreatitis [7] and
atherosclerosis [8]. Strategies to discover molecules that can
neutralize TLR4 signaling are thus predicted to show great
promise as novel anti-infective and/or anti-inflammatory agents.
The discovery of agents with anti-TLR4 properties has so far
been met with limited success, which until recently could be
attributed in part to a lack of reliable structural information on the
LPS signaling site on TLR4. Prior strategies to prevent LPS
signaling have therefore focused on the molecule LPS itself, which
is known to contain three distinct domains, including lipid A (the
bioactive component that is recognized in causing human
infection), a short oligosaccharide core, and the O-antigen
polysaccharide that varies in composition amongst gram-negative
bacterial strains [9]. The elucidation of the structure of LPS led to
the identification of the synthetic lipid A analogue eritoran
(E5564), as well as the lipid A mimetic CRX-526 in which the
reducing sugar on lipid A was replaced with an N-acylated
aminoalkyl saccharide [10]. Both E5564 and CRX-526 inhibited
LPS signaling, but, unfortunately, lacked efficacy in clinical trials
[11,12].
Recently, the crystal structure of the TLR4-MD2 complex with
bound E5564 was solved, which suggested that the mechanism of
action of E5564 involves its association with a large internal pocket
in the TLR4 co-receptor MD-2 [13]. This structural information
provides new opportunities for the design of novel E5564 analogs
with the ability to inhibit TLR4 signaling. We now report the
identification of a new class of small organic molecules with anti-
TLR4 properties and reveal the potential of our lead compound to
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serve as an anti-inflammatory agent in diseases characterized by
increased TLR4 signaling.
Materials and Methods
Assessment of TLR4 Inhibition in Mice
All mice were housed and cared for at the Rangos Research
Center of the Children’s Hospital of Pittsburgh (Pittsburgh, PA),
and all experiments were approved by the Institutional Review
Board of the University of Pittsburgh (Permit number: 12040382).
All studies were carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health.
Throughout the course of all experiments, mice were housed with
access to food, water and standard bedding. Endotoxemia was
induced in all experiments by intraperitoneal injection of LPS
(Escherichia coli 0111:B4 purified by gel filtration chromatography,
.99% pure, Sigma-Aldrich) at a dose of 3 mg/kg for 6 hours into
6 week old male mice. At the end of each experiment, all animals
were euthanized by CO2 and cervical dislocation. Immediately
prior to injection into mice, the compounds were diluted to an
experimental concentration of 100 uM in PBS, with the total
concentration of DMSO in the final diluted drug at 1%.
Compounds were closely examined to insure that no precipitate
formed prior to injection and were stored on ice until injection. In
all experiments listed, compounds were delivered to 6 week old
mice 30 minutes prior to injection with LPS. Control animals not
receiving compound received 1% DMSO dissolved in PBS
(‘‘vehicle controls’’). Where indicated, mice were also injected
with LPS along with the NFkB inhibitor Bay-11-7082 (20 mg/kg,
30 min pretreatment i.p., Cayman Chemical). In addition to
assessing the effect on clinical activity of the mice in which the
degree of piloerection, tachypnea and movement activity (huddled
in the corner versus roaming freely) were assessed, LPS and
individual compounds were also injected into NFkB-luciferase
reporter mice, in which NFkB is upstream of the luciferase gene
(strain NFkB-RE-luc, Taconic Farms Inc, Hudson, NY). In these
studies, 6h after LPS injection, mice were administered an i.p.
injection of luciferin (160 ug/kg, Caliper Life Sciences), then after
10 minutes, a whole animal image to evaluate luciferase activity
was obtained using the IVIS Lumina 3D Optical in vivo imaging
system (Caliper Life Sciences, Hopkinton, MA) under 1.5%
isofluorane anesthesia. Prior to being euthanized, mice from the
above experiments were anesthetized with 1.5% isofluorane and a
retro-orbital sinus puncture was performed to obtain a blood
sample; serum was obtained via centrifugation and ELISA was
performed to assess IL-6 expression (R&D Biosystems). The extent
of expression of the pro-inflammatory cytokines IL-6 and iNOS
within the intestinal mucosa was determined by RT-PCR (see
below).
In vitro Determination of TLR4 Inhibition
The ability of the individual compounds to inhibit TLR4 in vitro
was determined in cultured enterocytes (non-transformed rat small
intestinal IEC-6 cells) and monocytes (mouse RAW 264.7 cells).
Both IEC-6 cells and RAW 264.7 cells were obtained from the
American Type Culture Collection (ATCC, Manassas, VA). Cells
were treated with individual compounds at a concentration of
10 uM 30 min prior to treatment with LPS (LPS dose was 10 ng/
ml in RAW 264.7 cells, 10 ug/ml in IEC-6 cells), and the extent of
LPS signaling was determined by the degree of TNFa expression
by qRT-PCR. In parallel, RAW 264.7 cells were transduced with
an adenovirus expressing the NFkB-luciferase reporter gene – a
kind gift from Dr. Paul McCray, University of Iowa, as described
[14], and then treated with LPS at 10 ng/ml after pre-treatment
with the individual compounds at 100 mM. The NFkB-luciferase
activity was measured using the Luciferase Activity System
(Promega, Madison, WI) according to the manufacturer’s direc-
tions, and relative light units were normalized by total protein
content in each sample tested.
Synthesis of C34 and C35 and Preparation of Labeled 3H-
C35
The route for the synthesis of C34 that was used to validate the
structure of the commercial sample of this compound, as well as
the preparation of analog C35 and its tritiated derivative, 3H-C35
is described in detail below (see Results). A synthetic access to C34
was necessary since the commercial sample was of unknown
relative and absolute configuration. Spectral data for a validated
sample of C34:1H NMR (400 MHz, CDCl3) d 5.62 (d, J=9.6 Hz,
1 H), 5.19 (app t, J=9.6 Hz, 1 H), 5.10 (app t, J=9.6 Hz, 1 H),
4.92 (d, J=3.8 Hz, 1 H), 4.30 (td, J=3.6, 9.6 Hz, 1 H), 4.22 (dd,
J=4.8, 12.4 Hz, 1 H), 4.08 (dd, J=2.4, 12.4 Hz, 1 H), 4.03–3.99
(m, 1 H), 3.88 (sept, J=6.0 Hz, 1 H), 2.07 (s, 3 H), 2.02 (s, 3 H),
2.01 (s, 3 H), 1.93 (s, 3 H), 1.23 (d, J=6.4 Hz, 3 H), 1.14 (d,
J=6.4 Hz, 3 H); 13C NMR (100 MHz, CDCl3) d 171.4, 170.7,
169.8, 169.3, 95.7, 71.4, 71.0, 68.2, 67.7, 62.0, 51.8, 23.2, 23.1,
21.6, 20.7 (2 C), 20.6; HRMS (ESI) m/z calcd for C17H28NO9
(M+H) 390.1764, found 390.1790. A de novo synthesis was also
required to prepare a tritiated derivative of C35, which was
selected for labeling due to the equivalent bioactivity of C34 and
C35, and the relative ease to introduce tritium by tritiation of the
alkene precursor 4. In brief, a solution of 4 (0.4 mg, 0.001 mmol)
in anhydrous ethyl acetate (0.2 mL, 0.005 M) and 10% Pd/C
Table 1. Primers used in the current study.
Gene Forward primer Reverse Primer
Mouse GAPDH TGAAGCAGGCATCTGAGGG CGAAGGTGGAAGAGTGGGAG
Human GAPDH TCTCCTCTGACTTCAACAGCGACA CCCTGTTGCTGTAGCCAAATTCGT
Mouse IL6 CCAATTTCCAATGCTCTCCT ACCACAGTGAGGAATGTCCA
Human IL6 TCTCCACAAGCGCCTTCG CTCAGGGCTGAGATGCCG
Mouse TNFa TTCCGAATTCACTGGAGCCTCGAA TGCACCTCAGGGAAGAATCTGGAA
Human TNFa GGCGTGGAGCTGAGAGATAAC GGTGTGGGTGAGGAGCACA
Mouse iNOS CTGCTGGTGGTGACAAGCACATTT ATGTCATGAGCAAAGGCGCAGAAC
Human iNOS AATGAGTCCCCGCAGCCCCT AGTCATCCCGCTGCCCCAGT
doi:10.1371/journal.pone.0065779.t001
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(1 mg) was cooled to 278uC in a dry ice bath, evacuated at
278uC and pressurized to 635 Torr with tritium gas in a Trisorber
loaded with 45 Ci of tritium. The dry ice bath was removed,
allowing the pressure to rise to 800 Torr. Residual tritium gas
outside the reaction chamber was reabsorbed in the Trisorber.
After 4 h, the reaction mixture was cooled to 278uC and tritium
gas was reabsorbed until the pressure fell to 52 Torr. The mixture
was then stirred at room temperature overnight, allowing the
pressure to rise to 130 Torr. Nitrogen was used to increase the
internal pressure to 760 Torr before the reaction vessel was
removed from the Trisorber. The mixture was treated with
0.8 mL of ethyl acetate, filtered through a pad of celite and
glasswool in a Pasteur pipette and rinsed with 0.5 mL of ethyl
acetate. A total of 1.5 mL of solvent was collected in a 1.8 mL
screw top vial ( = ‘‘parent solution’’). Spectral data for C35 [15]:
1H NMR (400 MHz, CDCl3) d 5.57 (d, J=8.4 Hz, 1 H), 5.40
(app. t, J=9.2 Hz, 1 H), 5.04 (t, J=9.6 Hz, 1 H), 4.86 (d,
J=8.4 Hz, 1 H), 4.26 (dd, J=4.8, 12.0 Hz, 1 H), 4.10 (dd,
J=2.4, 12.0 Hz, 1 H), 3.72–3.58 (m, 3 H), 2.07 (s, 3 H), 2.02 (s,
3 H), 2.01 (s, 3 H), 1.93 (s, 3 H), 1.91–1.18 (m, 10 H); 13C NMR
(100 MHz, CDCl3) d 170.8, 170.2, 169.5, 98.9, 77.7, 72.1, 71.5,
68.9, 62.3, 55.5, 33.2, 31.6, 25.5, 23.8, 23.7, 23.4, 20.8, 20.7 (2 C).
An aliquot of 10 uL was removed, diluted in 1 mL of ethyl
acetate, and 10 uL of this mixture was analyzed in a Packard
scintillation counter, giving 4,500,000 cpm, equivalent to
90,000,000,000 dpm/mL of the original solution. Assuming
2,220,000,000 dpm/mCi, the original solution therefore has an
activity of approximately 40 mCi/mL, or a total of 60 mCi (ca.
150 mCi/mg) of 3H-C35, with an experimental specific activity of
60 mCi/umol. Of note, the calculated maximum specific activity
for 3H-C35 is 57.6 Ci/mmol, i.e. 57.6 mCi/umol, or 135 uCi/ug,
in excellent agreement with the measured value.
A sample of 0.25 mL of the parent solution was transferred into
a separate 1.8 mL screw top vial and evaporated under a nitrogen
stream to give 3H-C35 (estimated to be approximately 0.07 mg) as
a colorless residue. Based on the calculations of the parent
solution, this sample is estimated to contain slightly less than
10 mCi activity.
In vitro Assay to Measure TLR4 Binding
Wild type and TLR4 knockout bone marrow-derived macro-
phages (generous gift of Dr. Russ Salter, University of Pittsburgh)
were seeded onto 6 well plates and allowed to reach confluence,
which took ,2–3 days. The plates were chilled on ice and the cells
were washed four times with ice cold Hanks balanced salt solution
(HBSS) supplemented with 0.6% BSA. Prior to this time, a total of
2 nmol of 3H-C35, prepared as described above, was mixed with
2 mmol of unlabeled C35 in a total volume of 1 mL of HBSS
supplemented with 0.6% BSA. The unlabeled material enhanced
compound binding (data not shown) since the apparent K0.5 for
the cellular effects of C35 is relatively high (see text). Next, the
solution containing C35 was added onto the cells and incubated
for 1 hr on ice. The cells were then washed four times as before
and lysed in 1 ml of a solution containing 50 mM Tris pH 8,
100 mM EDTA, 0.4% sodium deoxycholate, and 1% NP-40 for
5 min on ice. The lysates were transferred to scintillation vials
containing 2 ml of ScintiSafe (ThermoFisher) and analyzed in a
Beckman LS6000IC scintillation counter.
Animal and Human Necrotizing Enterocolitis (NEC)
NEC was induced in neonatal mouse pups using our established
model as previously reported through the combination of the
administration of enteric formula and hypoxia in a manner that
results in patchy necrosis of the small and large intestine that
closely resembles clinical NEC. In brief, experimental NEC was
induced in 7–8 day old mice as we have previously described [16]
using formula gavage (Similac Advance infant formula (Abbott
Nutrition):Esbilac canine milk replacer 2:1) five times/day, and
hypoxia (5% O2, 95% N2) for 10 minutes in a hypoxic chamber
(Billups-Rothenberg) twice daily for 4 days. C34 was then
administered via the oral route at a concentration of 1 mg/kg
on each morning of the four day model. The severity of disease
was determined on histologic sections of the terminal ileum by a
pediatric pathologist who was blinded to the study condition
according to our previously published scoring system from 0
(normal) to 3 (severe) [17]. Sections of the terminal ileum were
harvested at the end of the model and processed for RNA, protein,
and immunopathology analysis [18].
Human tissue was obtained after written, informed consent was
received from the families of infants undergoing intestinal
resection for active NEC after the nature and possible conse-
quences of the studies were explained. The study was performed
under an active research protocol that had been approved by the
Institutional Review Board (IRB) of the University of Pittsburgh
(number PRO09110437), which has jurisdiction over all research
performed at the Children’s Hospital of Pittsburgh of the
University of Pittsburgh Medical Center (UPMC) which is the
site from which all the patient material was obtained.
After initial review by the duty pathologist to ensure that
adequate diagnostic information was obtained from the gross
tissue specimen, the intestinal resection was divided into multiple
pieces, and treated with either LPS 100 ng/ml, C34 alone (10 uM)
or LPS+ C34. After 3h, tissue was processed for RT-PCR, and
assessed for the expression of TNFa and iNOS. Data from
separate tissue harvests under each treatment group was then
pooled and statistical analysis was performed.
Figure 1. The novel inhibitor C34 blocks TLR4 signaling in vitro and in vivo. A: Pseudocolor images showing whole animal emission
corresponding to NFkB-luciferase activity in mice that were treated with either saline (i), C34 (1 mg/kg) (ii), LPS (3 mg/kg, iii), and LPS after the pre-
treatment with C34 (1 mg/kg, iv) 30 minutes prior; quantification (mean6SEM) is shown in v in which *p,0.05 LPS versus saline or C34 alone;
**p,0.005 LPS vs LPS+C34 or LPS+Bay11 (20 mg/kg); summary of 4 separate experiments with over 5 mice per group. B: qRT-PCR for IL-6 (i) and
iNOS (ii) in the small intestinal mucosa and IL-6 ELISA (iii) from the serum obtained from mice that were injected with either saline, LPS (3 mg/kg),
C34 (1 mg/kg) or LPS 30 minutes after pre-treatment with C34. In each graph, data are mean6SEM in which *p,0.05 LPS vs saline; **p,0.05 LPS vs
LPS+C34. Representative of 4 separate experiments with over 5 mice per group. C–D: Representative confocal micrographs showing the staining of
p65-NFkB subunit in either IEC-6 cells (C) or RAW 264.7 macrophages (D) that were treated with C34 (i, 10 uM), LPS (ii, 10 ug/mL for IEC-6, 10 ng/mL
for RAW 264.7), or LPS+C34 (iii). E: Quantification (mean6SEM) of NFkB translocation corresponding to experiments shown in Panels C and D for IEC-
6 (white bars) and RAW 264.7 (black bars) under the conditions indicated. F: qRT-PCR (mean6SEM) of TNFa in IEC-6 (white) and RAW (black) cells
under the conditions indicated; for E and F: *p,0.05 LPS vs saline or C34; **p,0.05 LPS vs LPS +C34 alone; G: luciferase activity in NFkB-luciferase
transformed RAW 264.7 cells that were treated with either saline (white bars) or C34 (black bars) then with either media alone or LPS, Pam3K or CpG-
DNA as indicated. Representative of 3 separate experiments; shown are mean6SEM. *p,0.05 LPS vs media; **p,0.05 LPS+saline vs LPS+C34 (C34 did
not inhibit either Pam3K or CpG-DNA treated cells). C34 was administered both in vivo and in vitro 30 minutes prior to LPS in all cases. The y axes in
panels B and F indicate the fold increase of the indicated gene relative to the housekeeping gene GAPDH.
doi:10.1371/journal.pone.0065779.g001
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Figure 2. Molecular interactions of C34 with the TLR4-MD2 complex. X-ray structure of E5564 (A and C) and docking model of C34 (B and D)
with the TLR4-MD2 complex, illustrating the interaction of E5563 and C34, respectively, with the hydrophobic groove of MD-2. Panel E displays the
amino acid residues on hMD2 within a 5 A˚ contact radius of C34. See Results for additional details.
doi:10.1371/journal.pone.0065779.g002
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RT-PCR
Total RNA was isolated from cultured enterocytes or ileal
mucosal scrapings from control and NEC mouse and human
intestine using the RNeasy kit (Qiagen), and reverse transcribed
(1 mg of RNA) using the QuantiTect Reverse Transcription Kit
(Qiagen). Quantitative real-time PCR was performed using the
ddCt method GAPDH as a housekeeping gene as we have
previously described [3,19–21] using the Bio-Rad CFX96 Real-
Time System (Biorad, Hercules, CA) using the primers described
in Table 1.
Statistical Analysis
All experiments were repeated at least in triplicate, with more
than 100 cells/high-power field. For endotoxemia, at least 3 mice/
group were assessed; for NEC, over 10 mouse pups per group were
included and litter matched controls were included in all cases.
Statistical analysis was performed using SPSS 13.0 software.
Figure 3. The C34 analog C35 inhibits TLR4 via direct binding. A: Synthesis of C34, its b-anomeric cyclohexyl analog C35 as well as the
corresponding tritiated derivative (3H-C35). B: i: Luciferase activity in NFkB-luciferase-transduced RAW 264.7 macrophages exposed to saline, LPS
(10 ng/ml), C35 (100 uM) or LPS 30 minutes after treatment with C35 as indicated. ii–iii: qRT-PCR showing the expression of TNFa (ii) and IL-6 (iii) in
the small intestinal mucosa of mice that were injected with saline, LPS (3 mg/kg), C35 (1 mg/kg) or LPS 30 minutes after treatment with C35. In panels
i–iii, *p,0.05 LPS vs saline treated mice or cells; **p,0.05 LPS vs LPS+C35 vs treated mice or cells. Representative of 3 separate experiments with at
least 3 mice per group. Data are mean6SEM. C: Raw radiation counts6103 from macrophages obtained from either wild-type or TLR42/2 mice that
had been treated with 50 mCi of 3H-C35, as described in Methods. The background emission is shown. Data are mean6SEM from 3 individual
experiments. *p,0.05 wild-type vs background; **p,0.05 TLR42/2 versus wild-type.
doi:10.1371/journal.pone.0065779.g003
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Figure 4. C34 attenuates intestinal inflammation in mouse and human NEC. A. Representative photomicrographs (i–iii) and gross images
(iv–vi) of the ileum from neonatal mice that were either breast fed (i, iv), induced to develop NEC along with vehicle (ii, v), or induced to develop
NEC in the presence of C34 (1 mg/kg daily) as described in Methods. B: qRT-PCR showing the expression of iNOS in the intestinal mucosa (i) and NEC
severity score (ii) of newborn mice that were either breast fed (‘‘BF’’) or induced to develop NEC in the absence (black bars) or presence (white bars)
Discovery of a Novel Class of TLR4 Inhibitors
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ANOVA was used for comparisons for experiments involving
more than two experimental groups. Two-tailed student’s t-test
was used for comparison for experiments consisting of two
experimental groups. For analysis of the severity of NEC, chi-
square analysis was performed. In all cases, statistical significance
was accepted at p,0.05 between groups.
Results
Selection of Potential TLR4 Inhibitors and Screening
Paradigm
In order to identify new TLR4 inhibitors, we performed in silico
similarity searches based on E5564 using the iResearch System
Library of ChemNavigatorH, the substance similarity Tanimoto
scores implemented in SciFinderH’s substructure module, and
ChemAxonH’s JChemH tools. From an initial yield of 700 hits,
,10% (68 individual compounds) were cherry picked based on
their commercial availability and chemical diversity. All members
of this subset were then evaluated for their ability to inhibit TLR4
signaling in mice after LPS injection, and confirmed in vitro for
their ability to inhibit LPS-induced TLR4 activation in both
hematopoietic and epithelial cells. One compound, C34, was
identified to meet or exceed our criteria of synthetic tractability,
assay robustness, potency, and selectivity. While a few other hits
were similarly potent, C34 had superior physicochemical proper-
ties. In particular, C34 has an attractive cLogP of 20.5, a
topological polar surface area (TPSA) of 126, which is well with
drug-like compound space, and passes both the Lipinski rules and
the Veber filter [22]. Data on the remaining compounds is not
included in the current manuscript. The parent compound C34
and the b-anomeric cyclohexyl analog C35, as well as a tritium-
labeled derivative, 3H-C35, were synthesized to confirm the
structural assignment, to establish a structure-activity relationship,
and to begin to characterize its mechanism of action.
In vivo Verification of TLR4 Inhibition by C34
Evidence in support of the ability of C34 to inhibit TLR4
signaling in vivo and in vitro is shown in Figure 1. To investigate
the degree to which C34 inhibits LPS signaling in vivo, we injected
LPS in the presence or absence of C34 into the NFkB-luciferase
transgenic mouse strain, in which the luciferase gene is placed
downstream of the TLR4-dependent transcription factor NFkB
[23]. LPS signaling was then assessed through measurements of
whole animal luciferase activity. As shown in Figure 1A, LPS
injection caused a marked increase in luciferase activity –
represented in pseudocolor format – which reveals the majority
of the luciferase signal localized to the intestines and the lymph
nodes within the neck. Pre-injection of mice with C34 30 minutes
prior significantly decreased luciferase (i.e., TLR4-NFkB) activity
in mice after LPS injection (Figure 1A iii versus iv and v). In
control experiments, pre-treatment with the NFkB inhibitor bay-
11 had a protective effect on the extent of LPS signaling as
measured by a reduction in the extent of luciferase activity that
was comparable to the effects of C34. Pre-treatment with C34 30
minutes prior also markedly reduced the extent of LPS-induced
IL-6 and iNOS expression in the intestinal mucosa as detected by
qRT-PCR (Figure 1B i and ii), and significantly reduced the
extent of IL-6 release into the serum as assessed by ELISA
(Figure 1B iii).
To determine whether C34 inhibits TLR4 signaling in vitro, we
treated IEC-6 enterocytes and RAW 264.7 macrophages with LPS
in the presence of C34 or vehicle control. LPS exposure activated
TLR4 signaling in macrophages and enterocytes, as manifested by
an increase in NFkB translocation from the cytoplasm to the
nucleus (Figure 1C–E), and an increase in the expression of
TNFa by RT-PCR (Figure 1F). Each of these events was
significantly reduced by pretreatment with C34 when adminis-
tered 30 minutes prior.
To evaluate whether the effects of C34 were specific for TLR4
agonists or whether C34 generally inhibited other TLRs, we
treated RAW 264.7 cells that were stably transduced with the
NFkB-luciferase gene with agonists for TLR4, TLR2 (Pam3K) or
TLR9 (CpG-DNA) in the presence or absence of C34. As shown
in Figure 1G, C34 only inhibited signaling via TLR4, and had no
statistically significant effect on signaling via any other TLR
receptor.
C34 Docks into the Hydrophobic Pocket in MD-2
Based on the crystal structure of the TLR4-MD-2 complex with
E5564 [13], we performed an in silico docking study with C34. The
compound was first minimized using the MM2 force field in
Scigress 7.7, and then superimposed on antagonist E5564. A
genetic algorithm using a potential of mean force (PMF) and a
maximum generation number of 3,000 was used to optimize the
binding mode. As shown in Figure 2, C34 slides deeper into the
hydrophobic grove of MD-2 than the disaccharide unit of E5564
(Figure 2B and D for C34 versus A and C for E5564), covering
some of the space that is otherwise occupied by the four acyl
chains of the endotoxin. There is sufficient room to accommodate
both a- and b-anomers of C34, as well as larger hydrophobic
anomeric substituents than i-propyl, which is in agreement with
the structure-activity relationships of this small molecule inhibitor.
The binding site for C34 is lined with mainly hydrophobic amino
acid side chains, including F121, F119, L61, I117, Y102, I94, V93,
F76, V135, and I78, with the notable exception of E92. The latter
residue is in close vicinity of the anomeric carbon of C34, pointing
its two methylene groups toward the isopropyl substituent of C34
and turning the carboxylate into the solvent space (Figure 2E).
The C34 Analog C35 Inhibits TLR4 via Direct Binding
To ascertain whether C34 binds to TLR4 directly, the b-
anomeric cyclohexyl analog C35 as well as the corresponding
tritiated derivative (3H-C35) were synthesized as shown in
Figure 3A. We then established that the unlabeled C35
compound significantly inhibited TLR4 signaling in vitro, as
measured by a loss of LPS-induced NFkB-luciferase activity in
RAW 264.7 cells (Figure 3B i), and in vivo, as measured by
reductions in LPS-induced expression of the pro-inflammatory
cytokines TNFa (Figure 3B ii) and IL-6 (Figure 3B iii) in the
intestinal mucosa of mice that had been injected with LPS in the
presence or absence of C35. To assess whether C35 directly
interacted with TLR4, we seeded wild type and TLR4-knockout
bone marrow-derived macrophages onto 6 well plates, and
incubated these cells with unlabeled C35 as well as tritiated 3H-
of C34 (1 mg/kg/day). Shown are mean6SEM. *p,0.05 vehicle NEC vs breast fed; **p,0.05 NEC+34 vs NEC+vehicle. Representative of 5 separate
experiments with over 5 neonatal mice per group. C: qRT-PCR showing expression of iNOS (i) and TNFa (ii) in the resected ileal tissue from neonates
with NEC that was subsequently treated with saline or LPS in the presence of vehicle or C34 for 3 hours. Shown is mean6SEM from 3 separate
specimens; *p,0.05 LPS vs saline; ***p,0.05 LPS+vehicle vs C34+ saline; **p,0.05 LPS+vehicle versus LPS+C34. The y axes in panels B and C indicate
the fold increase of the indicated gene relative to the housekeeping gene GAPDH.
doi:10.1371/journal.pone.0065779.g004
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C35. As shown in Figure 3C, 3H-
,
C34 Attenuates the Severity of Experimental NEC, a
Disease that Results from Exaggerated TLR4 Signaling
NEC is the leading cause of death from gastrointestinal disease
in premature infants, and is characterized by a marked increase in
acute inflammation of the intestinal mucosa that leads to epithelial
cell death and systemic sepsis [24]. Despite advances in neonatal
care, overall survival has remained unchanged in the past two
decades, in large part due to a lack of specific therapies for this
devastating disease [25]. We [26] and others [27] recently
determined that the development of NEC in mice, rats and
humans reflects increased TLR4 signaling in the premature host,
as exaggerated TLR4 signaling within the gut leads to increased
enterocyte apoptosis and elevated pro-inflammatory cytokine
release [3]. In order to test directly whether C34 could attenuate
NEC severity, we administered by oral gavage C34 in a well
validated model of experimental NEC in mice that consisted of
four days of formula by gavage as well as twice daily hypoxic
treatments [25]. NEC severity was measured by the degree of
inflammation within the intestinal mucosa and maintenance of the
mucosal architecture according to a validated scoring system, as
well as the extent of expression of the pro-inflammatory cytokine
iNOS within the intestinal mucosa [25]. Mice with NEC that were
administered saline alone demonstrated marked intestinal inflam-
mation and disruption of the intestinal mucosa (Figure 4A ii
versus i), necrosis of the small intestine (Figure 4A iv versus v),
increased expression of the pro-inflammatory cytokine iNOS in
the intestinal mucosa (Figure 4B i), and an increase in the NEC
severity score as we had previously validated [18] (Figure 4B ii).
Importantly, mice that received C34 demonstrated a marked
preservation of the intestinal mucosa (Figure 4A iii versus ii), a
reduction in the appearance of gross disease (Figure 4A v versus
vi), a reduction in the extent of pro-inflammatory iNOS
expression (Figure 4B i) and a reduction in NEC severity score
(Figure 4B ii). Taken together, these findings demonstrate that
the novel TLR4 inhibitor, C34, attenuates NEC severity.
C34 also Inhibits TLR4 Signaling in Human Tissue ex vivo
Obtained from Infants with NEC
In a final series of studies, we sought to evaluate whether C34
could inhibit TLR4 signaling in human intestinal tissue in patients
with NEC. To do so, we obtained freshly isolated small intestine
from human infants that had undergone surgical resection for
NEC, which necessarily requires the removal of a small amount of
inflamed yet viable tissue. After gross review by the pediatric duty
pathologist, the viable tissue was randomly sectioned into multiple
pieces, and treated with either LPS, LPS after C34 pre-treatment,
and C34 alone. As shown in Figure 4C i–ii, LPS significantly
increased the expression of iNOS (Figure 4C i) and TNFa
(Figure 4C ii), but this effect was reversed by pre-treatment with
C34. Of note, tissue that was treated with C34 alone showed a
marked decrease in TNFa expression without LPS treatment,
suggesting that C34 reduced ongoing inflammation in the resected
tissue. Taken together, our findings show that C34 decreases the
extent of LPS signaling in human tissue, and raises the exciting
possibility that C34 represents a new therapeutic option in diseases
associated with exaggerated TLR4 signaling, such as NEC.
Discussion
We report the results of a computational similarity search-
assisted drug discovery approach for the identification of a new
class of small organic molecules with shared structural identities
based on E5564. Through a series of confirmatory studies, we
established that our lead compound C34 inhibits TLR4 in vitro in
macrophages and enterocytes, and in vivo in experimental models
of endotoxemia and NEC. In addition, C34 reduced the degree of
LPS signaling in human tissue that was freshly removed from
infants with NEC. Based upon our current findings, we have
identified a new class of small molecules with therapeutic potential
in diseases that are characterized by exaggerated TLR4 signaling.
C34, which is a novel inhibitor of TLR4 in vitro and in vivo, has
the molecular formula of C17H27NO9, a molecular weight of
389.40, and a computed docking arrangement shown in Figure 2.
While we now describe the first report of this particular molecule
showing anti-TLR4 effects, the current findings are consistent with
other studies that have suggested a role for 2-amino-2-deoxyglyco-
sides as anti-inflammatory agents. Inhibitor E5564, which was
used as a reference structure for its ability to bind to TLR4 in the
initial in silico screen, has a 2-acylamidopyranoside substructure.
Furthermore, the N-acetyl-glucosamine scaffold has known anti-
inflammatory effects in a variety of cells, including retinal pigment
epithelial cells [28], endothelial cells [29], mast cells [30] and
peritoneal mesothelial cells [31], providing further evidence for the
role for this class of molecules as TLR4 inhibitors. Interestingly,
Lee and colleagues also recently showed that a novel aminosac-
charide has anti-TLR effects in macrophages in vitro [32]. Based
on these findings, we submit that per-acylated 2-aminopyranoses
with alkyl side chains at the anomeric carbon, in particular those
with similarity to our lead compound, C34, have the potential to
elicit broad and beneficial clinical effects in diseases characterized
by TLR4 hyperactivation. Given that the development of
necrotizing enterocolitis occurs almost exclusively in premature
infants after they have received oral feeds, and given our findings
that the development of NEC reflects increased signaling via
TLR4 in the intestinal epithelium of the premature gut
[3,16,18,26,33], it is exciting to speculate that a feeding regimen
which contains a TLR4 inhibitor such as C34 may be of benefit in
the prevention of NEC in this population.
An exciting and rather serendipitous discovery in the current
work links our identification of this aminoglycoside scaffold (i.e.,
C34 and the closely related b-anomeric cyclohexyl analog C35) to
the treatment of experimental NEC, a disease that we and others
have shown to be mediated via TLR4 activation in mice and
humans [26,27]. Although a cure for NEC remains elusive, there
is consensus that the administration of breast milk is the most
effective preventive strategy [26,27]. While the precise mecha-
nisms to explain the protective effects of breast milk remain
unknown, an emerging body of literature has determined that
breast milk-derived oligosaccharides exert anti-inflammatory
properties, and that these molecules may be responsible in part
for the protective effects of breast milk in NEC. For instance,
human milk oligosaccharides reduce leukocyte adhesion to
endothelial cells [34], reduce platelet-leukocyte adhesion [35],
alter the composition of the microbiome [36], and alter the degree
of adherence of certain microbes to the surface of the intestinal
epithelium [37]. The specific mechanisms by which human milk
oligosaccharides exert these protective effects remain incompletely
understood. Given our finding that simple aminomonosaccharides
serve as TLR4 inhibitors, it is possible that human milk
oligosaccharides convey their anti-inflammatory function in part
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    ~ 
C35 bound RAW 264.7
macrophages that expressed TLR4 1.5-fold better than 
TLR4-deficient cells. Taken together, the data presented in
Figures 1 and 3 strongly suggest that both C34 and   C35
interact directly with TLR4.
through a previously unrecognized inhibitory effect on TLR4
signaling.
In summary, we have identified a new class of small molecule
inhibitors of TLR4, which show substantial benefits in models of
experimental NEC. These findings suggest a viable approach for
the development of novel therapies for a variety of infectious and
inflammatory diseases in which TLR4 signaling plays a critical
role.
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